# A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

> **NCT04665063** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Auto CAR-T
- **DRUG:** Cyclophosphamide,Fludarabine
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT04665063
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-22
- **Primary completion:** 2023-10-21
- **Final completion:** 2025-10-21
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665063, "A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04665063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*